Sign In
Buy AORT
$26.83
-0.84 (-3.04%)
At Close: Jul 31, 2026
Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock
04:01pm, Wednesday, 14'th May 2025
ATLANTA , May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately
Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript
10:37pm, Monday, 05'th May 2025
Artivion, Inc. (NYSE:AORT ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief F
Artivion (AORT) Lags Q1 Earnings Estimates
06:51pm, Monday, 05'th May 2025
Artivion (AORT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.06 per share a year ago.
Artivion Reports First Quarter 2025 Financial Results
04:05pm, Monday, 05'th May 2025
First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP const
30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA , May 5, 2025 /PRNewswire/ -- Artivion
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results
04:10pm, Monday, 21'st Apr 2025
ATLANTA , April 21, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial resul
Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength?
10:11am, Thursday, 10'th Apr 2025
Artivion (AORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
04:05pm, Tuesday, 04'th Mar 2025
ATLANTA , March 4, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at th
Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround
10:35am, Thursday, 27'th Feb 2025
Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript
11:00pm, Monday, 24'th Feb 2025
Artivion, Inc. (NYSE:AORT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - C
Artivion (AORT) Reports Break-Even Earnings for Q4
06:21pm, Monday, 24'th Feb 2025
Artivion (AORT) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.12. This compares to earnings of $0.11 per share a year ago.
Artivion Reports Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Monday, 24'th Feb 2025
Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP co
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results
04:10pm, Monday, 10'th Feb 2025
ATLANTA , Feb. 10, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 f
On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks.
03:09pm, Monday, 03'rd Feb 2025
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA , Jan. 27, 2025 /PRNewswire/ -- Artivion, I
